ISM6331
Insilico Medicine: company profile
Phase 1/2 registry
Since , the date of the source that reports this phase.
Summary
ISM6331 is a program from Insilico Medicine. The source describes it as small molecule. It is being developed for mesothelioma and solid tumors. ClinicalTrials.gov lists it at Phase 1/2 (recruiting) under NCT06566079. The AI role named in the source is molecule design. Registry records: NCT06566079, Phase 1/2, recruiting, updated Sep 16, 2026. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. First patient dosed. The latest dated source is from Jan 23, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Mesothelioma and solid tumors
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 1/2, as of Jan 23, 2025
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
First patient dosed
AI evidence
AI source: Company
“Insilico Medicine to Present First-in-Human Data for AI-Designed Pan-TEAD Inhibitor ISM6331 at ESMO 2026”
Trial records
- NCT06566079 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Recruiting Updated
Milestone timeline
-
Official X post: Phase 1/2
First patient dosed
-
NCT06566079 record updated
Phase 1/2, Recruiting
-
Registry check
Registry Phase 1/2 vs post Phase 1.
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.